Literature DB >> 20235083

Intrathoracic manifestations of cervical anastomotic leaks after transhiatal and transthoracic oesophagectomy.

M van Heijl1, A K S van Wijngaarden, S M Lagarde, O R C Busch, J J B van Lanschot, M I van Berge Henegouwen.   

Abstract

BACKGROUND: A possible advantage of cervical oesophagogastrostomy over intrathoracic anastomosis after oesophagectomy is the presumed mild clinical course of cervical anastomotic leakage. The incidence and consequences of intrathoracic manifestations after cervical anastomotic leakage remain unclear, and were investigated in this study.
METHODS: Consecutive patients undergoing potentially curative transhiatal oesophagectomy (THO) or transthoracic oesophagectomy (TTO) with cervical oesophagogastrostomy between 1993 and 2007 were included. Intrathoracic manifestations after cervical anastomotic leakage were compared following THO and TTO. Multivariable logistic regression analysis was used to identify potential risk factors for intrathoracic manifestations.
RESULTS: Seventy-nine (15.8 per cent) of 501 patients developed anastomotic leakage after THO compared with 50 (15.3 per cent) of 327 after TTO (P = 0.853). Intrathoracic manifestations developed in 21 (27 per cent) and 22 (44 per cent) patients respectively (P = 0.041). A transthoracic approach was the only independent predictor of the development of intrathoracic manifestations in patients with cervical leakage (odds ratio 2.60; P = 0.022). Total hospital stay (P < 0.001), intensive care unit stay (P < 0.001) and in-hospital mortality (P = 0.035) were greater in patients with intrathoracic manifestations than in those without.
CONCLUSION: Intrathoracic manifestations of cervical anastomotic leakage are associated with a prolonged hospital stay, carry a higher mortality and occur more frequently after TTO than THO. Copyright 2010 British Journal of Surgery Society Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20235083     DOI: 10.1002/bjs.6971

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  7 in total

1.  Application of Oesophagogastric Cervical Mechanical Anastomosis in Oesophagectomy for Cancer.

Authors:  Zhong Chen; Ning Zhang; Xiao Chen
Journal:  Indian J Surg       Date:  2014-04-22       Impact factor: 0.656

Review 2.  Transthoracic vs transhiatal surgery for cancer of the esophagogastric junction: a meta-analysis.

Authors:  Ming-Tian Wei; Yuan-Chuan Zhang; Xiang-Bing Deng; Ting-Han Yang; Ya-Zhou He; Zi-Qiang Wang
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Early severe mediastinal bleeding after esophagectomy: a potentially lethal complication.

Authors:  Jeroen E H Ponten; Sylvia van der Horst; Grard A P Nieuwenhuijzen; Ted W O Elenbaas; Richard van Hillegersberg; Misha D P Luyer
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

4.  A high body mass index in esophageal cancer patients does not influence postoperative outcome or long-term survival.

Authors:  R L G M Blom; S M Lagarde; J H G Klinkenbijl; O R C Busch; M I van Berge Henegouwen
Journal:  Ann Surg Oncol       Date:  2011-10-07       Impact factor: 5.344

Review 5.  Anastomotic leakage after esophagectomy for esophageal cancer: definitions, diagnostics, and treatment.

Authors:  M Fabbi; E R C Hagens; M I van Berge Henegouwen; S S Gisbertz
Journal:  Dis Esophagus       Date:  2021-01-11       Impact factor: 3.429

6.  Application of mediastinal drainage tube in intrathoracic esophageal anastomotic leakage for early diagnosis and effective treatment: a retrospective study.

Authors:  Hainong Ma; Xu Song; Jie Li; Guofang Zhao
Journal:  J Cardiothorac Surg       Date:  2021-03-25       Impact factor: 1.637

7.  Intrathoracic versus Cervical ANastomosis after minimally invasive esophagectomy for esophageal cancer: study protocol of the ICAN randomized controlled trial.

Authors:  Frans van Workum; Stefan A W Bouwense; Misha D P Luyer; Grard A P Nieuwenhuijzen; Donald L van der Peet; Freek Daams; Ewout A Kouwenhoven; Marc J van Det; Frits J H van den Wildenberg; Fatih Polat; Suzanne S Gisbertz; Mark I van Berge Henegouwen; Joos Heisterkamp; Barbara S Langenhoff; Ingrid S Martijnse; Janneke P Grutters; Bastiaan R Klarenbeek; Maroeska M Rovers; Camiel Rosman
Journal:  Trials       Date:  2016-10-18       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.